Chemotherapy Induced Neuropathic Pain Clinical Trial
Official title:
Prospective Open Labeled Pilot Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
The goal of this clinical research study is to learn about the effectiveness of quercetin in treating and preventing CINP. Researchers also want to learn if quercetin has an effect on participant's quality of life.
Study Product Administration:
If participant is found to be eligible to take part in this study, participant will take
quercetin tablets by mouth 2 times every day for 12 weeks. The study staff will give
participant the tablets and additional instructions on how to take the study product.
Length of Participation:
Participant may take quercetin for up to 12 weeks. Participant will no longer be able to take
quercetin if the pain symptoms gets worse, if intolerable side effects occur, or if
participant is unable to follow study directions.
Study Visits:
Every week, participant will either come to the clinic or a member of the staff will call
participant to learn how participant is doing, if participant has had any side effects, and
to check that participant is taking quercetin correctly. Participant will also complete a
questionnaire about any pain symptoms participant may be having. The call/questionnaire
should take about 10-15 minutes to complete.
End-of-Study Visit:
About 7 days after participant's last dose of quercetin, participant will complete the same
questionnaires participant completed at screening.
Participation in this study will be over after the end-of-study visit.
This is an investigational study. Quercetin is commercially available as a supplement, but it
is not FDA approved.The study doctor can explain how the study product is designed to work.
Up to 20 participants will be enrolled in this study. All will take part at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00407511 -
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
|
Phase 4 |